 |
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hormone
|
 |
|
Title:
|
 |
A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist
|
|
Structure:
|
 |
Hepatocyte growth factor. Chain: a, b. Fragment: residues 28-209. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: hgf, hpta. Expressed in: escherichia coli. Expression_system_taxid: 562.
|
|
Resolution:
|
 |
|
1.81Å
|
R-factor:
|
0.201
|
R-free:
|
0.248
|
|
|
Authors:
|
 |
W.D.Tolbert,J.Daugherty,C.-F.Gao,Q.Xe,C.Miranti,E.Gherardi, G.Vande Woude,H.E.Xu
|
Key ref:
|
 |
W.D.Tolbert
et al.
(2007).
A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist.
Proc Natl Acad Sci U S A,
104,
14592-14597.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
06-Jul-07
|
Release date:
|
18-Sep-07
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
|
|
P14210
(HGF_HUMAN) -
Hepatocyte growth factor
|
|
|
|
Seq: Struc:
|
 |
 |
 |
728 a.a.
174 a.a.
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Biological process
|
blood coagulation
|
2 terms
|
 |
|
Biochemical function
|
calcium ion binding
|
2 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Proc Natl Acad Sci U S A
104:14592-14597
(2007)
|
|
PubMed id:
|
|
|
|
|
| |
|
A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist.
|
|
W.D.Tolbert,
J.Daugherty,
C.Gao,
Q.Xie,
C.Miranti,
E.Gherardi,
G.Vande Woude,
H.E.Xu.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Hepatocyte growth factor (HGF) activates the Met receptor tyrosine kinase by
binding and promoting receptor dimerization. Here we describe a mechanistic
basis for designing Met antagonists based on NK1, a natural variant of HGF
containing the N-terminal and the first kringle domain. Through detailed
biochemical and structural analyses, we demonstrate that both mouse and human
NK1 induce Met dimerization via a conserved NK1 dimer interface. Mutations
designed to alter the NK1 dimer interface abolish its ability to promote Met
dimerization but retain full Met-binding activity. Importantly, these NK1
mutants act as Met antagonists by inhibiting HGF-mediated cell scattering,
proliferation, branching, and invasion. The ability to separate the Met-binding
activity of NK1 from its Met dimerization activity thus provides a rational
basis for designing Met antagonists. This strategy of antagonist design may be
applicable for other growth factor receptors by selectively abolishing the
receptor activation ability but not the receptor binding of the growth factors.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 2.
Fig. 2. Met dimerization induced by NK1 binding. (A) A
diagram of AlphaScreen assay for detecting Met dimerization
promoted by NK1 binding. (B) Met dimerization induced by 1
µM NK1 in the presence and absence of 10 µM heparin
as measured by AlphaScreen assays. (C) Dose curves of various
NK1 to induce Met dimerization in the presence of 10 µM
heparin.
|
 |
Figure 3.
Fig. 3. Crystal structures of the mouse and human NK1. (A)
An overall view of the head-to-tail dimer of the mouse NK1. The
letters (K, D, Y, and N) indicate the position of residues K85,
D123, Y124, and N127, respectively. Only yellow monomer is
labeled. (B) The NK1 dimer interface and the intermolecular
interactions. The interface within 6.0 Å of the other
monomer is shown as a purple surface and inner residues are
gold, green, and red if they are within 4.0, 5.0, and 6.0
Å, respectively, of the other NK1. The list of
interactions includes non-H-bond packing and H-bond interactions
within 4.0 Å between the two NK1 monomers. Double-headed
arrows indicate reciprocal interactions between two monomers and
single-headed arrows indicate interactions from one monomer to
the other. Underlining indicates that the residues' protein
backbone atoms are involved in dimer interactions. (C)
Interactions mediated by Y124 and K85 (yellow monomer) with
V140, D202, I203, and P204 (cyan monomer). Hydrogen bonds are
indicated by dashed lines. Water-mediated interactions are
indicated by W1 and W2. (D) Interactions mediated by K122, D123,
and N127 (yellow monomer) with K122, D123, and N127 (cyan
monomer). Hydrogen bonds are indicated by dashed lines. (E)
Comparison of the mouse and human NK1 (superposition of the C
atoms). The two mouse
monomers are in yellow and cyan, and the human monomers are in
gold and blue. Arrows indicate the heparin binding sites
identified in previous studies (23).
|
 |
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
S.Mostowy,
S.Janel,
C.Forestier,
C.Roduit,
S.Kasas,
J.Pizarro-Cerdá,
P.Cossart,
and
F.Lafont
(2011).
A role for septins in the interaction between the Listeria monocytogenes INVASION PROTEIN InlB and the Met receptor.
|
| |
Biophys J, 100,
1949-1959.
|
 |
|
|
|
|
 |
B.J.Yamamoto,
P.D.Elias,
J.A.Masino,
B.D.Hudson,
A.T.McCoy,
Z.J.Anderson,
M.D.Varnum,
M.F.Sardinia,
J.W.Wright,
and
J.W.Harding
(2010).
The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor.
|
| |
J Pharmacol Exp Ther, 333,
161-173.
|
 |
|
|
|
|
 |
H.R.Maun,
D.Kirchhofer,
and
R.A.Lazarus
(2010).
Pseudo-active sites of protease domains: HGF/Met and Sonic hedgehog signaling in cancer.
|
| |
Biol Chem, 391,
881-892.
|
 |
|
|
|
|
 |
W.D.Tolbert,
J.Daugherty-Holtrop,
E.Gherardi,
G.Vande Woude,
and
H.E.Xu
(2010).
Structural basis for agonism and antagonism of hepatocyte growth factor.
|
| |
Proc Natl Acad Sci U S A, 107,
13264-13269.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
J.M.Schultz,
S.N.Khan,
Z.M.Ahmed,
S.Riazuddin,
A.M.Waryah,
D.Chhatre,
M.F.Starost,
B.Ploplis,
S.Buckley,
D.Velásquez,
M.Kabra,
K.Lee,
M.J.Hassan,
G.Ali,
M.Ansar,
M.Ghosh,
E.R.Wilcox,
W.Ahmad,
G.Merlino,
S.M.Leal,
S.Riazuddin,
T.B.Friedman,
and
R.J.Morell
(2009).
Noncoding mutations of HGF are associated with nonsyndromic hearing loss, DFNB39.
|
| |
Am J Hum Genet, 85,
25-39.
|
 |
|
|
|
|
 |
S.Taouji,
S.Dahan,
R.Bossé,
and
E.Chevet
(2009).
Current Screens Based on the AlphaScreen Technology for Deciphering Cell Signalling Pathways.
|
| |
Curr Genomics, 10,
93.
|
 |
|
|
|
|
 |
A.A.Pioszak,
and
H.E.Xu
(2008).
Molecular recognition of parathyroid hormone by its G protein-coupled receptor.
|
| |
Proc Natl Acad Sci U S A, 105,
5034-5039.
|
 |
|
PDB code:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|